Alnylam to Present Additional Patisiran Data For Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals is set to present additional data from its APOLLO-B Phase 3 study on Patisiran for Cardiomyopathy of ATTR Amyloidosis at the Heart Failure Society of America Annual Scientific Meeting in 2023.
October 06, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam's presentation of additional Patisiran data could potentially impact the company's stock depending on the results.
The presentation of additional data from Alnylam's APOLLO-B Phase 3 study could potentially influence investor sentiment towards the company. Positive results could boost the company's stock, while negative results could have the opposite effect. However, the exact impact is uncertain until the data is presented.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100